The Repeated Administration of Resveratrol Has Measurable Effects on Circulating T-Cell Subsets in Humans

Oxidative Medicine and Cellular Longevity

Volumn 2017, Issue , 2017, Pages

  Espinoza, J Luis ^a   Trung, Ly Quoc ^a,b   Inaoka, Pleiades T ^a   Yamada, Kayoko ^a   An, Dao T ^a   Mizuno, Shohei ^c   Nakao, Shinji ^a   Takami, Akiyoshi ^c  

^a KANAZAWA UNIVERSITY   (Japan)

^b Phuong Chau International Hospital   (Viet Nam)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANTS; CYTOLOGY; RESVERATROL; T-CELLS;

AUTOIMMUNE DISORDER; BIOLOGICAL EFFECTS; IMMUNOMODULATORY EFFECTS; NATURALLY OCCURRING; PLASMA ANTIOXIDANT ACTIVITIES; PRECLINICAL STUDIES; PRO-INFLAMMATORY CYTOKINES; REGULATORY T CELLS;

CELLS;

8 HYDROXYDEOXYGUANOSINE; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NATURAL KILLER CELL RECEPTOR NKG2D; RESVERATROL; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; ANTIOXIDANT; CHEMOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; STILBENE DERIVATIVE;

ADULT; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOCOMPETENT CELL; IN VITRO STUDY; JAPANESE (PEOPLE); MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; REPEATED DRUG DOSE; T LYMPHOCYTE SUBPOPULATION; URINE SAMPLING; BLOOD; CELL MOTION; CLINICAL TRIAL; CYTOLOGY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

CELLS; DISEASES; MEDICINE;

ADULT; ANTIOXIDANTS; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; STILBENES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 85019589303     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2017/6781872     Document Type: Article

References (45)

1. R. Kotecha, A. Takami, J. L. Espinoza, "Dietary phytochemicalsand cancer chemoprevention: A review of theclinical evidence, " Oncotarget, vol. 7, no. 32, pp. 52517-52529, 2016.
2. J. Burns, T. Yokota, H. Ashihara, M. E. Lean, A. Crozier, "Plant foods and herbal sources of resveratrol, " Journal ofAgricultural and Food Chemistry, vol. 50, no. 11, pp. 3337-3340, 2002.
3. R. G. Britton, C. Kovoor, K. Brown, "Direct molecular targetsof resveratrol: Identifying key interactions to unlock complexmechanisms, " Annals of the New York Academy ofSciences, vol. 1348, no. 1, pp. 124-133, 2015.
4. J. Gambini, M. Inglés, G. Olaso, et al., "Properties of resveratrol:in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans, " OxidativeMedicine and Cellular Longevity, vol. 2015, p. 837042, 2015.
5. K. R. Patel, E. Scott, V. A. Brown, A. J. Gescher, W. P. Steward, and K. Brown, "Clinical trials of resveratrol, " Annals of theNew York Academy of Sciences, vol. 1215, no. 1, pp. 161-169, 2011.
6. D. J. Boocock, G. E. Faust, K. R. Patel, et al., "Phase I dose escalationpharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent, " CancerEpidemiology, Biomarkers & Prevention, vol. 16, no. 6, pp. 1246-1252, 2007.
7. K. R. Patel, V. A. Brown, D. J. Jones, et al., "Clinical pharmacologyof resveratrol and its metabolites in colorectal cancerpatients, " Cancer Research, vol. 70, no. 19, pp. 7392-7399, 2010.
8. O. Vang, N. Ahmad, C. A. Baile, et al., "What is new for an oldmolecule Systematic review and recommendations on the useof resveratrol, " PLoS One, vol. 6, no. 6, article e19881, 2011.
9. A. Movahed, I. Nabipour, X. Lieben Louis, et al., "Antihyperglycemiceffects of short term resveratrol supplementation intype 2 diabetic patients, " Evidence-Based Complementary andAlternative Medicine, vol. 2013, p. 851267, 2013.
10. R. S. Turner, R. G. Thomas, S. Craft, et al., "A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimerdisease, " Neurology, vol. 85, no. 16, pp. 1383-1391, 2015.
11. V. A. Brown, K. R. Patel, M. Viskaduraki, et al., "Repeat dosestudy of the cancer chemopreventive agent resveratrol inhealthy volunteers: Safety, pharmacokinetics, effect onthe insulin-like growth factor axis, " Cancer Research, vol. 70, no. 22, pp. 9003-9011, 2010.
12. C. la Porte, N. Voduc, G. Zhang, et al., "Steady-state pharmacokineticsand tolerability of trans-resveratrol 2000 mg twicedaily with food, quercetin and alcohol (ethanol) in healthyhuman subjects, " Clinical Pharmacokinetics, vol. 49, no. 7, pp. 449-454, 2010.
13. J. Luis Espinoza, A. Takami, L. Q. Trung, S. Nakao, "Ataxia-telangiectasia mutated kinase-mediated upregulationof NKG2D ligands on leukemia cells by resveratrol results inenhanced natural killer cell susceptibility, " Cancer Science, vol. 104, no. 6, pp. 657-662, 2013.
14. L. Hu, D. Cao, Y. Li, Y. He, K. Guo, "Resveratrol sensitizedleukemia stem cell-like KG-1a cells to cytokine-induced killercells-mediated cytolysis through NKG2D ligands and TRAILreceptors, " Cancer Biology & Therapy, vol. 13, no. 7, pp. 516-526, 2012.
15. J. Yao, C. Wei, J. Y. Wang, R. Zhang, Y. X. Li, L. S. Wang, "Effect of resveratrol on Treg/Th17 signaling and ulcerativecolitis treatment in mice, " World Journal of Gastroenterology, vol. 21, no. 21, pp. 6572-6581, 2015.
16. CTCAECV 4. 0April 2013, http://evs. Nci. Nih. Gov/ftp1/ctcae/ctcae-4. 03-2010-06-14-quickreference-5x7. Pdf.
17. J. L. Espinoza, D. T. An, L. Q. Trung, K. Yamada, S. Nakao, A. Takami, "Stilbene derivatives from melinjo extract haveantioxidant and immune modulatory effects in healthy individuals, "Integrative Molecular Medicine, vol. 2, no. 6, pp. 405-413, 2015.
18. C. Berzosa, I. Cebrián, L. Fuentes-Broto, et al., "Acute exerciseincreases plasma total antioxidant status and antioxidantenzyme activities in untrained men, " Journal of Biomedicine& Biotechnology, vol. 2011, p. 540458, 2011.
19. C. S. Erdogan and O. Vang, "Challenges in analyzing the biologicaleffects of resveratrol, " Nutrients, vol. 8, no. 6, p. 353, 2016.
20. L. Almeida, M. VazdaSilva, A. Falcaõ, et al., "Pharmacokineticand safety profile of trans-resveratrol in a risingmultiple-dose study in healthy volunteers, " Molecular Nutrition& Food Research, vol. 53, Supplement 1, pp. S7-15, 2009.
21. C. H. Cottart, V. Nivet-Antoine, J. L. Beaudeux, "Reviewof recent data on the metabolism, biological effects, toxicityof resveratrol in humans, " Molecular Nutrition & FoodResearch, vol. 58, no. 1, pp. 7-21, 2014.
22. M. Moniuszko, K. Kowal, S. Zukowski, M. Dabrowska, A. Bodzenta-Lukaszyk, "Frequencies of circulating CD4+CD25+CD127low cells in atopics are altered by bronchial allergenchallenge, " European Journal of Clinical Investigation, vol. 38, no. 3, pp. 201-204, 2008.
23. V. Lafont, F. Sanchez, E. Laprevotte, et al., "Plasticity of Tcells: Impact on the anti-tumor response, " Frontiers in Immunology, vol. 5, p. 622, 2014.
24. S. A. Long and J. H. Buckner, "CD4+FoxP3+ T regulatory cellsin human autoimmunity: More than a numbers game, "Journal of Immunology, vol. 187, no. 5, pp. 2061-2066, 2011.
25. J. M. Smoliga, E. S. Colombo, M. J. Campen, "A healthierapproach to clinical trials evaluating resveratrol for primaryprevention of age-related diseases in healthy populations, "Aging (Albany NY), vol. 5, no. 7, pp. 495-506, 2013.
26. B. Silva-Santos, K. Serre, H. Norell, " T cells in cancer, "Nature Reviews. Immunology, vol. 15, pp. 683-691, 2015.
27. J. L. Espinoza, V. H. Nguyen, H. Ichimura, et al., "A functionalpolymorphism in the NKG2D gene modulates NK-cell cytotoxicityand is associated with susceptibility to human papillomavirus-related cancers, " Scientific Reports, vol. 6, p. 39231, 2016.
28. N. Guerra, Y. X. Tan, N. T. Joncker, et al., "NKG2D-deficientmice are defective in tumor surveillance in models of spontaneousmalignancy, " Immunity, vol. 28, no. 4, pp. 571-580, 2008.
29. M. Liu, S. A. Wilk, A. Wang, et al., "Resveratrol inhibits mTORsignaling by promoting the interaction between mTOR andDEPTOR, " The Journal of Biological Chemistry, vol. 285, no. 47, pp. 36387-36394, 2010.
30. H. Kopf, G. M. de la Rosa, O. M. Howard, X. Chen, "Rapamycininhibits differentiation of Th17 cells and promotesgeneration of FoxP3+ T regulatory cells, " International Immunopharmacology, vol. 7, no. 13, pp. 1819-1824, 2007.
31. G. M. Delgoffe, T. P. Kole, Y. Zheng, et al., "The mTORkinase differentially regulates effector and regulatory T celllineage commitment, " Immunity, vol. 30, no. 6, pp. 832-844, 2009.
32. A. R. Hussain, S. Uddin, R. Bu, et al., "Resveratrol suppressesconstitutive activation of AKT via generation of ROS andinduces apoptosis in diffuse large B cell lymphoma cell lines, "PloS One, vol. 6, no. 9, article e24703, 2011.
33. X. Chen, M. Song, B. Zhang, Y. Zhang, "Reactive oxygenspecies regulate T cell immune response in the tumor microenvironment, "Oxidative Medicine and Cellular Longevity, vol. 2016, p. 1580967, 2016.
34. D. Mougiakakos, C. C. Johansson, R. Kiessling, "Naturallyoccurring regulatory T cells show reduced sensitivity towardoxidative stress-induced cell death, " Blood, vol. 113, no. 15, pp. 3542-3545, 2009.
35. H. S. Zahedi, S. Jazayeri, R. Ghiasvand, M. Djalali, M. R. Eshraghian, "Effects of Polygonum cuspidatum containing resveratrolon inflammation in male professional basketballplayers, " International Journal of Preventive Medicine, vol. 4, Supplement 1, pp. S1-S4, 2013.
36. M. Kunz and S. M. Ibrahim, "Cytokines and cytokine profiles inhuman autoimmune diseases and animal models of autoimmunity, "Mediators of Inflammation, vol. 2009, p. 979258, 2009.
37. B. B. Aggarwal, S. C. Gupta, J. H. Kim, "Historical perspectiveson tumor necrosis factor and its superfamily: 25 years later, a golden journey, " Blood, vol. 119, no. 3, pp. 651-665, 2012.
38. F. Carbone, V. De Rosa, P. B. Carrieri, et al., "Regulatory T cellproliferative potential is impaired in human autoimmune disease, "Nature Medicine, vol. 20, no. 1, pp. 69-74, 2014.
39. M. Shakibaei, K. B. Harikumar, B. B. Aggarwal, "Resveratroladdiction: To die or not to die, " Molecular Nutrition &Food Research, vol. 53, no. 1, pp. 115-128, 2009.
40. L. B. Sullivan and N. S. Chandel, "Mitochondrial reactive oxygenspecies and cancer, " Cancer & Metabolism, vol. 2, no. 1, p. 17, 2014.
41. M. Ralser and H. Lehrach, "Building a new bridge betweenmetabolism, free radicals and longevity, " Aging (Albany NY), vol. 1, no. 10, pp. 836-838, 2009.
42. C. Richardson, S. Yan, C. G. Vestal, "Oxidative stress, bone marrow failure, genome instability in hematopoieticstem cells, " International Journal of Molecular Sciences, vol. 16, no. 2, pp. 2366-2385, 2015.
43. D. P. Jones, "Redox theory of aging, " Redox Biology, vol. 5, pp. 71-79, 2015.
44. A. Valavanidis, T. Vlachogianni, C. Fiotakis, "8-hydroxy-2-deoxyguanosine (8-OHDG): A critical biomarker of oxidativestress and carcinogenesis, " Journal of Environmental Scienceand Health. Part C, Environmental Carcinogenesis &Ecotoxicology Reviews, vol. 27, no. 2, pp. 120-139, 2009.
45. L. L. Wu, C. C. Chiou, P. Y. Chang, J. T. Wu, "Urinary 8-OHDG: A marker of oxidative stress to DNA and a risk factorfor cancer, atherosclerosis and diabetics, " Clinica ChimicaActa, vol. 339, no. 1, pp. 1-9, 2004.